Na\textsubscript{v}1.7: Stress-induced changes in immunoreactivity within magnocellular neurosecretory neurons of the supraoptic nucleus

Joel A Black\textsuperscript{1,2}\textsuperscript{*}, Janneke GJ Hoeijmakers\textsuperscript{3}, Catharina G Faber\textsuperscript{3}, Ingemar SJ Merkies\textsuperscript{3,4} and Stephen G Waxman\textsuperscript{1,2}†

Abstract

Background: Na\textsubscript{v}1.7 is preferentially expressed, at relatively high levels, in peripheral neurons, and is often referred to as a “peripheral” sodium channel, and Na\textsubscript{v}1.7-specific blockers are under study as potential pain therapeutics which might be expected to have minimal CNS side effects. However, occasional reports of patients with Na\textsubscript{v}1.7 gain-of-function mutations and apparent hypothalamic dysfunction have appeared. The two sodium channels previously studied within the rat hypothalamic supraoptic nucleus, Na\textsubscript{v}1.2 and Na\textsubscript{v}1.6, display up-regulated expression in response to osmotic stress.

Results: Here we show that Na\textsubscript{v}1.7 is present within vasopressin-producing neurons and oxytocin-producing neurons within the rat hypothalamus, and demonstrate that the level of Nav1.7 immunoreactivity is increased in these cells in response to osmotic stress.

Conclusions: Na\textsubscript{v}1.7 is present within neurosecretory neurons of rat supraoptic nucleus, where the level of immunoreactivity is dynamic, increasing in response to osmotic stress. Whether Na\textsubscript{v}1.7 levels are up-regulated within the human hypothalamus in response to environmental factors or stress, and whether Na\textsubscript{v}1.7 plays a functional role in human hypothalamus, is not yet known. Until these questions are resolved, the present findings suggest the need for careful assessment of hypothalamic function in patients with Na\textsubscript{v}1.7 mutations, especially when subjected to stress, and for monitoring of hypothalamic function as Na\textsubscript{v}1.7 blocking agents are studied.

Keywords: Hypothalamus, Na\textsubscript{v}1.7, Salt-loading, Supraoptic nucleus

Background

Gain-of-function mutations of the Na\textsubscript{v}1.7 sodium channel, which is preferentially expressed at relatively high levels within peripheral (dorsal root ganglion and sympathetic ganglion) neurons \cite{1-3} produce several syndromes associated with severe pain, including inherited erythromelalgia \cite{4-8} and paroxysmal extreme pain disorder \cite{9,10} as well as painful small-fiber neuropathy \cite{11,12}, while loss-of-function mutations of Na\textsubscript{v}1.7 cause channelopathy-associated insensitivity to pain \cite{13-15}. In contrast with the severe pain associated with gain-of-function mutations of Na\textsubscript{v}1.7 and loss of pain sensitivity associated with loss-of-function mutations of Na\textsubscript{v}1.7, abnormalities of CNS function have in general not been reported in these disorders, consistent with preferential expression of Na\textsubscript{v}1.7 within peripheral neurons. Na\textsubscript{v}1.7-specific blockers are being studied as potential therapies for pain, with the rationale that they would be expected to have few, if any, CNS-related side-effects. Nevertheless, there have been reports of hypothermia, possibly due to an abnormality of central (hypothalamic) thermoregulation \cite{16-18} in patients with Na\textsubscript{v}1.7 mutations and erythromelalgia. The syndrome of inappropriate release of antidiuretic hormone, SIADH, without any structural cause, recently developed in a patient carrying a gain-of-function mutation of Na\textsubscript{v}1.7, G856D, within a kindred with painful small-fiber neuropathy (Hoeijmakers et al, personal communication). Affected family members, all of whom carry the G856D mutation, display small-fiber

* Correspondence: stephen.waxman@yale.edu
† Equal contributors
1 Department of Neurology, Yale University School of Medicine, New Haven, CT 06510, USA
2 Center for Neuroscience and Regeneration Research, Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA
Full list of author information is available at the end of the article

© 2013 Black et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
neuropathy characterized by severe pain and vasomotor dyscontrol in their distal extremities, small hands and feet, and autonomic dysfunction. The G856D mutation enhances channel activation, impairs fast-inactivation, and markedly enhances the channel’s persistent current and response to slow ramp stimuli. The occurrence of SIADH in this patient suggested the possibility that the gain-of-function mutation in Na\textsubscript{v}1.7 might have contributed to hyperexcitability of vasopressin-releasing (magnocellular neurosecretory) neurons in the supraoptic nucleus within the hypothalamus.

Vasopressin release by supraoptic magnocellular neurons can be triggered by osmotic stress and depends on bursting activity in these cells [19]. It is known that tetrodotoxin-sensitive sodium channels contribute to this bursting [20-22]. While high levels of expression of Na\textsubscript{v}1.7 have been reported in hypothalamic nuclei including the supraoptic nucleus in rodents [13,23], only weak levels of Na\textsubscript{v}1.7 expression were detected within the primate supraoptic nucleus [13]. In the present study, we have built upon earlier studies in rodents which showed that the deployment of sodium channels in the hypothalamus is dynamic, with levels of expression of the two sodium channel subtypes that were previously studied, Na\textsubscript{v}1.2 and Na\textsubscript{v}1.6, and of sodium channel beta-1 and beta-2 subunits and sodium currents, displaying up-regulation within supraoptic magnocellular neurons exposed to osmotic stress via salt-loading [24] and as a result of the hyperosmolar state associated with experimental diabetes [25]. Reasoning that Na\textsubscript{v}1.7 expression within supraoptic magnocellular neurons might be subject to similar plasticity, we exposed rats to salt-loading and assessed the level of Na\textsubscript{v}1.7 immunoreactivity within these neurons. We demonstrate here that Na\textsubscript{v}1.7 is present within vasopressin- and oxytocin-producing neurons of the supraoptic nucleus, and show that the level of Na\textsubscript{v}1.7 protein in these cells is not static but, on the contrary, is increased in response to salt-loading.

**Results**

Previous work from our laboratory has demonstrated the expression of the tetrodotoxin-sensitive (TTX-S) sodium channels, Na\textsubscript{v}1.2 and Na\textsubscript{v}1.6, but not Na\textsubscript{v}1.1 and Na\textsubscript{v}1.3, and of TTX-S sodium currents in magnocellular neurosecretory cells (MSC) of the hypothalamic supraoptic nucleus [24]. This early study also showed that the expression of Na\textsubscript{v}1.2 and Na\textsubscript{v}1.6 channels are upregulated and amplitude of the sodium current increased following salt-loading challenge [24]. To determine whether Na\textsubscript{v}1.7 is expressed and upregulated in magnocellular neurosecretory cells of the supraoptic nucleus, we assessed the supraoptic nucleus of control and salt-loaded (2% NaCl in drinking water) rats using immunocytochemistry. Measurement of plasma osmotic pressure confirmed the presence of hyperosmolality in the salt-loaded rats: control, 323.3 ± 4.8 mOsm; salt-loaded, 353.2 ± 3.3 mOsm (p < 0.05).

Magnocellular neurosecretory cells in the supraoptic nucleus of control rats exhibited distinct Na\textsubscript{v}1.7 immunolabeling (Figure 1). Some magnocellular neurosecretory cells displayed moderate levels of Na\textsubscript{v}1.7 immunosignal, while other magnocellular neurosecretory cells exhibited a low level or no Na\textsubscript{v}1.7 immunofluorescence. Two types of magnocellular neurosecretory cells exist within the supraoptic nucleus, oxytocin-producing and vasopressin-producing, with little co-expression of these hormones in individual magnocellular neurosecretory cells. Both oxytocin- and vasopressin-producing magnocellular neurosecretory cells displayed Na\textsubscript{v}1.7 immunolabeling (Figure 1). Approximately 72% (33 of 46) of oxytocin-producing and 53% (59 of 112) of vasopressin-producing MSC expressed Na\textsubscript{v}1.7 labeling above background levels.

Salt-loading induced a substantial increase in the level of Na\textsubscript{v}1.7 immunoreactivity in magnocellular neurosecretory cells of the supraoptic nucleus compared to magnocellular neurosecretory cells in control rats (Figure 2A). In addition to the detection of greater numbers of magnocellular neurosecretory cells that displayed Na\textsubscript{v}1.7 immunolabeling, the intensity of Na\textsubscript{v}1.7 signal was increased in response to salt-loading.

![Figure 1 Na\textsubscript{v}1.7 expression in vasopressin- and oxytocin-producing magnocellular neurosecretory cells in supraoptic nucleus.](http://www.molecularpain.com/content/9/1/39)
in some magnocellular neurosecretory neurons was markedly greater than that observed in magnocellular neurosecretory cells from control rats. Quantification of the mean intensity of Nav1.7 signal within the circumscribed supraoptic nucleus demonstrated a significant up regulation of Nav1.7 in response to salt-loading challenge (Figure 2B). These observations demonstrate that, in addition to up regulation of the TTX-S sodium channels NaV1.2 and NaV1.6 within magnocellular neurosecretory cells of the supraoptic nucleus with salt-loading, the level of Nav1.7 protein in these cells is significantly increased in osmotically-challenged rats.

Discussion
In this study we have demonstrated that Nav1.7 is present within neurons within the hypothalamic supraoptic nucleus, specifically within vasopressin- and oxytocin-producing magnocellular neurosecretory neurons. We also show that the level of Nav1.7 protein in these cells is not fixed but, on the contrary, is dynamic, increasing as a result of salt-loading.

A role Nav1.7 in electrogensis in DRG neurons is well-established, and it is clear that Nav1.7 functions as a threshold channel in these neurons, amplifying small depolarizing inputs to bring the cell to threshold for action potential generation [26,27] and possibly facilitating invasion into, and/or transmitter release from, pre-terminal axons within the spinal cord dorsal horn [1,28]. In contrast, a functional role of Nav1.7 within supraoptic neurons is less well understood. Action potential bursts, triggered by osmotic changes, lead to release of vasopressin by supraoptic magnocellular neurons [19] and it is known that tetrodotoxin-sensitive sodium channels contribute to this bursting [20-22].

Supraoptic magnocellular neurons are known to be highly dynamic. It is known that, in response to changes in osmolality, the expression of peptides within these cells changes, and they change in size [29]. In parallel, it has been shown that in response to increased osmolality there are changes in deployment of sodium channels, with up-regulated expression of the NaV1.2 and NaV1.6 alpha subunits, and of the sodium channel beta-1 and beta-2 subunits [24,25]. The present results show that the level of Nav1.7 protein, like that of NaV1.2 and NaV1.6 [24,25], is dynamic, and is up-regulated within supraoptic magnocellular neurons exposed to osmotic stress via salt-loading. A previous study [24] demonstrated an increase in the amplitude of the transient Na+ current, and an even greater increase in the amplitude and density of the Na+ currents evoked by slow ramp stimuli in supraoptic neurons following salt-loading. While definitive identification of the current as Nav1.7 current would require specific blockade or knockout, both of these types of current have been observed to be produced by Nav1.7 [26]. Because Nav1.7 is present within vasopressin neurons, it seems likely that this sodium channel isoform plays some role in vasopressin release in response to the osmotic stress imposed by salt-loading.

Although only low levels of Nav1.7 have been reported in the hypothalamus in primates [13], it is possible that the density of Nav1.7 channels within magnocellular neurons of the human supraoptic nucleus, like that in rodents, is subject to up-regulation in response to some forms of stress. Nav1.7 channels are absent beginning in early embryogenesis in affected individuals in these families, and the possibility that there might be compensatory changes in hypothalamic neurons which maintain relatively normal function in these cells cannot be excluded. Whether levels of Nav1.7 are increased in response to environmental
factors or stress within the human hypothalamus, and whether NaV1.7 plays a functional role in hypothalamic neurons in humans, is not known. Until these questions are resolved, the present findings suggest the need for assessment of hypothalamic function in patients carrying NaV1.7 mutations especially when subjected to stress, and for monitoring of hypothalamic function as NaV1.7 blocking agents are studied.

Conclusions
In summary, our results demonstrate that sodium channel NaV1.7 is expressed in vasopressin-producing and oxytocin-producing magnocellular neurosecretory neurons of the rat hypothalamic supraoptic nucleus. The level of NaV1.7 immunoreactivity in the supraoptic nucleus is significantly increased following salt-loading, suggesting a contribution of NaV1.7 in the response of magnocellular neurosecretory neurons to osmotic stress. While it is not yet known whether levels of expression of NaV1.7 are increased in response to environmental factors or stress within the human hypothalamus, or whether NaV1.7 plays a functional role in hypothalamic neurons in humans, the present findings suggest the need for assessment of hypothalamic function in patients carrying NaV1.7 mutations, especially when subjected to stress, and for monitoring of hypothalamic function as NaV1.7 blocking agents are studied.

Methods
Salt loading
Adult male Sprague-Dawley rats (200-220 g), housed under a 12 h-12 h dark-light cycle, were salt-loaded with 2% NaCl (ad libitum) in their drinking water and unlimited access to food. Rats were sacrificed for immunocytochemical investigation 7 days following salt loading. All experiments were approved by the VA Connecticut Healthcare System Institutional Animal Care and Use Committee. To confirm the extent of salt loading, plasma osmotic pressure of the rats was measured (vapor pressure osmometer model 5500, Wescor, USA). Body weights were significantly (p < .05) lower in salt-loaded (186.6 ± 4.7 g) compared to control (248.6 ± 1.9 g). Six control and 6 salt-loaded rats were used for the immunocytochemistry studies.

Immunocytochemistry
Rats were perfused with 4% paraformaldehyde in 0.14 M Sorensen's phosphate buffer, pH 7.4, and the brain removed and postfixed for 25-30 minutes. After cryoprotection in 30% sucrose in 0.01 M PBS for 24 h, the brains were blocked, frozen and coronal cryosections (16 μm) containing SON and optic chiasm were cut. Sections were incubated in blocking solution (PBS containing 3% normal donkey serum, 3% fish skin gelatin, 0.1% Triton X-100 and 0.02% sodium azide) for 15 min at room temperature, primary antibody(ies) [rabbit anti- NaV1.7, 1:200, Y083 (Black et al. 2012); guinea pig anti-vasopressin, 1:100, Peninsula Lab, San Carlos, CA); mouse anti-oxytocin, 1:500, Abcam, Cambridge, MA] in blocking solution 2-4 days at 4°C, rinsed in PBS, incubated 1-2 days at 4°C with secondary antibody(ies) [donkey anti-rabbit Alexa Fluor-488-conjugated F(ab')2 fragment, donkey anti-rabbit Alexa Fluor-Cy3, donkey anti-guinea pig Alexa Fluor-488; donkey anti-mouse Alexa Fluor-488; all secondary antibodies from Jackson Immuno Research, West Grove, PA], rinsed with PBS and mounted on glass slides with Aqua-polymount (Polyscience, Warrington, PA). Control experiments in which the primary antibody was omitted exhibited only background levels of labeling.

Quantification
Tissue sections were examined with a Nikon C1 confocal microscope (Nikon USA, Melville, NY), using a 20x objective and operating in single mode for detection of NaV1.7 alone or in frame lamba (sequential) mode for detection of NaV1.7 and vasopressin or oxytocin to prevent possible bleed-through between 488 and Cy3 channels. For detection of NaV1.7 in the supraoptic nucleus (SON), images were acquired from 6 control and 6 salt-loaded rats, utilizing the same confocal settings for acquisition of NaV1.7 immunofluorescent signals. Images were opened in Nikon Elements and the mean signal intensity of the circumscribed SON was calculated by the software.

For co-localization of NaV1.7 and vasopressin or oxytocin in SON neurons, signals for NaV1.7 and vasopressin were thresholded at intensities 20% above background levels, and the percentage of vasopressin neurons expressing NaV1.7 was calculated. Data are presented as mean ± SEM and statistical analysis was performed with Excel Student’s t-test, with p < .05 considered significant.

Abbreviations
DRG: Dorsal root ganglion; MSN: Magnocellular neurosecretory neurons; SIADH: Syndrome of inappropriate release of anti-diuretic hormone; SON: Supraoptic nucleus.

Competing interests
The authors declare no competing interests.

Authors’ contributions
JAB designed immunocytochemical experiments, acquired, analyzed and interpreted data, and participated in writing manuscript. JGJH participated in conception and design of experiments and to editing the manuscript. CGF participated in conception and design of experiments and to editing the manuscript. SJM participated in conception and design of experiments and to editing the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors thank Shujun Liu and Pamela Zwinger for excellent technical assistance. This work was supported by the Medical Research Service and
Rehabilitation Research Service, Department of Veterans Affairs. The Center for Neuroscience and Regeneration Research is a Collaboration of the Paralyzed Veterans of America with Yale University.

Author details 1Department of Neurology, Yale University School of Medicine, New Haven, CT 06510, USA. 2Center for Neuroscience and Regeneration Research, Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA. 3Department of Neurology, University Medical Center Maastricht, Maastricht, the Netherlands. 4Department of Neurology, Spaarne Hospital, Hoofddorp, the Netherlands.

Received: 17 June 2013 Accepted: 6 August 2013

References
1. Dib-Hajj SD, Yang Y, Black JA, Waxman SG: The Na(V)1.7 sodium channel: from molecule to man. Nat Rev Neurosci 2013, 14(1):49-62.
2. Rush AM, Dib-Hajj SD, Liu S, Cummings TR, Black JA, Waxman SG: A single sodium channel mutation produces hyper- or hypo excitability in different types of neurons. Proc Natl Acad Sci USA 2006, 103(21):8245-8250.
3. Toledo-Aral JJ, Moss BL, He ZJ, Koszowski AG, Whisenand T, Levinson SR, Waxman SG: Gain-of-function mutation in Na(V)1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 2005, 128(Pt 8):1847-1854.
4. Han C, Dib-Hajj SD, Waxman SG: Inherited erythromelalgia: limb pain from an S4 charge-neutral Na channelopathy. Neurology 2006, 67(9):1563-1567.
5. Cummings TR, Dib-Hajj SD, Waxman SG: Electrophysiological properties of mutant Na(V)1.7 sodium channels in a painful inherited neuropathy. J Neurosci 2004, 24(36):8232-8236.
6. Dib-Hajj SD, Rush AM, Cummings TR, Hisama FM, Novella S, Tyrrell L, Marshall L, Waxman SG: Gain-of-function mutation in Na(V)1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 2005, 128(Pt 8):1847-1854.
7. Han C: Novel SCN9A mutations in a painful inherited peripheral neuropathy. J Neurosci 2009, 31(1):1226-1239.
8. Han C, Rush AM, Dib-Hajj SD, Li S, Xu Z, Yang Y, Liu M, Black JA, Waxman SG: Sporadic onset of inherited erythromelalgia: a gain-of-function mutation in Na(V)1.7. J Neurol 2006, 253(7):767-774.
9. Dib-Hajj SD, Estacion M, Jarecki BW, Tyrrell L, Fischer TZ, Lawden M, Cummings TR, Waxman SG: Paroxysmal extreme pain disorder M162K mutation in human Na(V)1.7 renders DRG neurons hyperexcitable. Mol Pain 2008, 4:337.
10. Fertleman CR, Baker MD, Parker KA, Moffatt S, Emslie FI, Abrahamsen B, Ostman J, Klugbauer N, Wood JD, Gardiner RM, et al: SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuroen 2006, 52(5):553-558.
11. Faber CG, Hoejmakers JG, Agh HS, Cheng X, Han C, Choi JS, Estacion M, Lauria G, Vanhoutte EM, Greer MM, et al: Gain of function of Na(V)1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol 2012, 71(2):126-39.
12. Han C, Hoejmakers JG, Agh HS, Zhao P, Shah P, Lauria G, Greer MM, Te Moro RH, Dib-Hajj SD, Drenth JP, et al: Na(V)1.7-related small fiber neuropathy: Impaired slow-inactivation and DRG neuron hyper excitability. Neurology 2012, 78(11):1635-1643.
13. Ahmad S, Dhallulid L, Eriksson A, Hellgren J, Lauria S, Black JA, Wahlstrom F, Pejler G, Moller J, et al: A stop codon mutation in SCN9A causes lack of pain sensation. Hum Mol Genet 2007, 16(17):2114-2121.
14. Cox J, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafari H, Mannan J, Rashid Y, et al: An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006, 444(7121):894-898.
15. Goldberg YP, MacFarlane J, MacDonald ML, Thompson J, Dube MP, Mattice M, Fraser R, Young C, Hosain S, Pape T, et al: Loss-of-function mutations in the Na(V)1.7 sodium channel underlie congenital indifference to pain in multiple human populations. Clin Genet 2007, 71(4):311-319.
16. Misery L, Greco M, Fleuret C, Firmin D, Mocquard Y, Renault A, Roguedas AM: Severe neurological complications of hereditary erythromelalgia. J Eur Acad Dermatol Venereol 2007, 21(10):1446-1447.
17. Seneschal J, Sole G, Taieb A, Ferrer X: A case of primary erythromelalgia with encephalopathy. J Neurol 2009, 256(10):1767-1768.